Meu SciELO
Serviços Personalizados
Artigo
Indicadores
- Citado por SciELO
Links relacionados
- Similares em SciELO
Compartilhar
Correo Científico Médico
versão On-line ISSN 1560-4381
Resumo
REMEDIOS BATISTA, Susel E et al. Cyclophosphamide in the Systemic Sclerosis Treatment. ccm [online]. 2015, vol.19, n.4, pp. 706-717. ISSN 1560-4381.
A search on the history of different therapies use in patients with systemic sclerosis was done, the advantages of the use of cyclophosphamide was approached, therapeutic failure and tested, present and future possibilities, in order to demonstrate the advantages of using cyclophosphamide as first-line therapy in patients included in different studies, and sensitize the scientific community of the specialty of rheumatology, on the risk benefit of using this drug in patients with a disease of a very poor prognosis . The selection of patients with systemic sclerosis will undergo treatment with cyclophosphamide in controlled studies required preclinical or early phases without any of its existing clinical forms exclusion, irreversibility showing severe forms of the disease, as well as the period duration of two years less medication could be causes of treatment failure. The results of this comprehensive review motivate the scientific community to insist on how to use it.
Palavras-chave : systemic sclerosis; diffuse interstitial disease; cyclophosphamide.